| 764318 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
235 Novel biparatopic TIM-3 antibody effectively blocks multiple inherent ligands and activates anti-tumor immunity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.235 |
Mishima Yuji, Nakajima Kanto, Shiraishi Mamoru, Matsumura Haruka, Aramaki Takahiko, Matsumoto Noriko, Nakamura Norihiro |
| 764317 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
234 Distinct efficacy and immunological responses to αPD-1, αPD-L1 and αPD-L2 immunotherapy in aged versus young hosts |
2021-11-01 |
10.1136/jitc-2021-sitc2021.234 |
Deng Yilun, Gupta Harshita, Garcia Myrna, Kancharla Aravind, Reyes Ryan, Padron Alvaro, Curiel Tyler |
| 764316 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
233 Human PD-L2 triggers a unique T cell inhibitory program through PD-1 engagement distinct from that of PD-L1 |
2021-11-01 |
10.1136/jitc-2021-sitc2021.233 |
Srinivasamani Anupallavi, Curran Michael, Liu Qinying, Hegde Shwetha, Chen Chao-Hsien, Rajapakshe Kimal, Coarfa Cristian |
| 764315 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
232 INCB090244, a potent small molecule that inhibits the PD-L1/PD-1 axis and functions similarly to PD-L1 antibodies |
2021-11-01 |
10.1136/jitc-2021-sitc2021.232 |
Rios-Doria Jonathan, Volgina Alla, Gokhale Prafulla, Liu Hao, Stevens Christina, Zolotarjova Nina, DiMatteo Darlise, Kapilashrami Kanishk, Behshad Elham, Thekkat Pramod, Yang Gengjie, Hall Leslie, Kanellopoulou Chrysi, Rupar Mark, Maddage Christopher, Horsey April, Burke Krista, Yang Yan-ou, Covington Maryanne, Wang Steve, Liu Phillip, Wynn Richard, Reardon David, Koblish Holly |
| 764314 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
230 Preclinical efficacy of CLEC-1 antagonist as novel myeloid immune checkpoint therapy for oncology |
2021-11-01 |
10.1136/jitc-2021-sitc2021.230 |
Gauttier Vanessa, Drouin Marion, Pengam Sabrina, Saenz Javier, Evrard Bérangère, Neyton Stéphanie, Mary caroline, Teppaz Géraldine, Desselle Ariane, Thépénier Virginie, Wilhelm Emmanuelle, Poirier Nicolas, Chiffoleau Elise |
| 764313 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
228 Antagonistic pH-selective VISTA antibody SNS-101 potentiates anti-PD-1/PD-L1-induced anti-tumor immunity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.228 |
Thisted Thomas, Mukherjee Arnab, Malhotra Kanam, Biesova Zuzana, Kleschenko Yuliya, Jiang Zhi-Gang, Cifuentes Anokhi, Boland Nadthakarn, Nielson Nels, Horst Edward van der |
| 764312 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
259 Injectable chitosan hydrogel for localized delivery of immune checkpoint inhibitors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.259 |
Mantooth Siena, Zaharoff David, Mantooth Siena |
| 764311 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
381 Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study |
2021-11-01 |
10.1136/jitc-2021-sitc2021.381 |
Bifulco Carlo, Richards Jon, Hyngstrom John, Daniels Gregory, Faries Mark, Feun Lynn, Margolin Kim, Hallmeyer Sigrun, Grose Mark, Zhang Yiwei, Li Anlong, Andtbacka Robert HI |
| 764310 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
258 AB308 is an anti-TIGIT antibody that enhances immune activation and anti-tumor immunity alone and in combination with other I-O therapeutic agents |
2021-11-01 |
10.1136/jitc-2021-sitc2021.258 |
Piovesan Dana, Lopez Alejandra, Schweickert Patrick, Soriano Ferdie, Cho Soonweng, Chen Ada, Singh Hema, Zhao Xiaoning, Young Stephen, Walker Nigel, Walters Matthew, Gauthier Kelsey Sivick |
| 764309 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
255 Investigating VISTA’s role intrinsic to T cells in the tumor microenvironment |
2021-11-01 |
10.1136/jitc-2021-sitc2021.255 |
Gilmour Cassandra, Wang Li, Dong Juan, Stone Sarah, Zhang Keman, Ta Hieu |
